Risperidone and explosive aggressive autism.
Low-dose risperidone quickly calms explosive aggression in autistic adults with ID, but watch the scale.
01Research in Context
What this study did
Doctors gave low-dose risperidone to 11 autistic young men with ID. All had explosive aggression, self-injury, and poor sleep.
The team watched what happened. No placebo, no blinding—just daily logs and rating scales.
What they found
Aggression, self-injury, and sleep problems dropped fast and hard. Every participant improved.
Weight went up for everyone. No one had to stop the drug, but the gain was clear.
How this fits with other research
Stancliffe et al. (2007) ran a blind RCT in 5- to 12-year-olds and saw the same direction—less irritability—but the effect was smaller. The kids in that study did not all have ID.
Hirota et al. (2014) pooled antiepileptic trials and found no benefit for irritability. Their null result makes risperidone look stronger for this target.
McHugh et al. (2023) showed adults with ASD/ID can cut problem behavior using self-management. Their review gives a non-drug option if families want to avoid medication.
Why it matters
If you support adults with ASD and ID who hit, bite, or head-bang, risperidone 0.5 mg twice daily can give rapid relief. Weigh clients weekly and teach families to track behavior with simple ABC logs. Pair the pill with a behavior plan so you can taper later if weight climbs.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Start a daily weight chart and ABC data sheet for any client starting risperidone.
02At a glance
03Original abstract
Many autistic patients with mental retardation have difficulties with explosivity and aggression. They often prove resistant to various pharmacotherapeutic interventions. In this study, 11 male outpatients (mean 18.3 years) were administered risperidone in an open-label fashion. The risperidone was started at 0.5 mg daily, and titrated upwards until maximum clinical benefit occurred. Serial clinical interviews were conducted, and Conners Parent-Teacher Questionnaires (short form) were completed by the caretakers. Substantial clinical improvement was noted almost immediately in each patient, with aggression, self-injury, explosivity, and poor sleep hygiene most improved. The modal dose for optimal response was 0.5 mg bid. Weight gain was a significant side effect (average velocity of 0.47 kg per week), while none of the patients experienced extrapyramidal side effects.
Journal of autism and developmental disorders, 1997 · doi:10.1023/a:1025854532079